$ASMB

VENTRUS BIOSCIENCES INC

CIK:0001426800|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Income Statement [Abstract]

Collaboration revenue from a related party

$ 13,374

$ 9,626

$ 21,587

$ 19,045

Operating expenses

Research and development

14,917

16,125

29,817

30,976

General and administrative

^[1]

4,801

4,594

9,484

9,103

Total operating expenses

19,718

20,719

39,301

40,079

Loss from operations

(6,344)

(11,093)

(17,714)

(21,034)

Other income

Interest and other income, net

2,487

895

4,778

2,018

Total other income

2,487

895

4,778

2,018

Net loss

(3,857)

(10,198)

(12,936)

(19,016)

Other comprehensive loss

Unrealized loss on marketable securities

255

582

Comprehensive loss

$ (4,112)

$ (10,224)

$ (13,518)

$ (19,084)

Net loss per share, basic

$ (0.2)

$ (1.33)

$ (0.72)

$ (2.51)

Net loss per share, diluted

$ (0.2)

$ (1.33)

$ (0.72)

$ (2.51)

Weighted average common shares outstanding, basic

18,853,646

7,655,854

17,882,335

7,581,501

Weighted average common shares outstanding, diluted

18,853,646

7,655,854

17,882,335

7,581,501

[1]	Includes stock-based compensation expense, see Note 7 - Stock-Based Compensation for further details.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (12,936)	$ (19,016)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	46	65
Stock-based compensation	3,532	1,546
Net accretion of investments in marketable debt securities	(1,557)	(887)
Non-cash rent expense	407	438
Changes in operating assets and liabilities:
Accounts receivable from collaboration with a related party	152	0
Prepaid expenses and other current assets	(1,326)	937
Accounts payable	(112)	158
Accrued research and development expenses	(380)	(582)
Other accrued expenses	(4,407)	(3,455)
Deferred revenue from a related party	(20,600)	(19,045)
Operating lease liabilities	(404)	(356)
Net cash used in operating activities	(37,585)	(40,197)
Cash flows from investing activities
Proceeds from maturities of marketable securities	111,355	60,932
Purchases of marketable securities	(208,799)	(37,352)
Purchases of property and equipment	(19)	0
Net cash (used in) provided by investing activities	(97,463)	23,580
Cash flows from financing activities
Proceeds from the issuance of common stock and pre-funded warrants in an underwritten offering, net of issuance costs ($12,500 from a related party)	108,080	0
Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs	0	1,922
Proceeds from the issuance of common stock under ESPP	425	357
Proceeds from the exercise of stock options	379	0
Net cash provided by financing activities	108,884	2,279
Net decrease in cash and cash equivalents	(26,164)	(14,338)
Cash and cash equivalents at the beginning of the period	58,450	38,344
Cash and cash equivalents at the end of the period	32,286	24,006
Supplemental non-cash investing and financing activities
Purchases of property and equipment included in accounts payable	$ 121	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 32,286	$ 58,450
Marketable securities	288,075	189,656
Accounts receivable from collaboration with a related party	822	974
Prepaid expenses and other current assets	6,795	5,469
Total current assets	327,978	254,549
Property and equipment, net	315	221
Operating lease right-of-use (ROU) assets	2,227	2,508
Other assets	312	312
Total assets	330,832	257,590
Current liabilities
Accounts payable	1,180	1,171
Accrued research and development expenses	2,007	2,387
Other accrued expenses	3,342	7,749
Deferred revenue from a related party	16,304	36,904
Operating lease liabilities - short-term	612	569
Total current liabilities	23,445	48,780
Operating lease liabilities - long-term	1,738	2,059
Total liabilities	25,183	50,839
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 19,850,342 and 15,855,329 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	20	16
Additional paid-in capital	1,151,235	1,038,823
Accumulated other comprehensive loss	(623)	(41)
Accumulated deficit	(844,983)	(832,047)
Total stockholders' equity	305,649	206,751
Total liabilities and stockholders' equity	$ 330,832	$ 257,590